A phase 1/2a trial of amsulostat, a novel pan-lysyl oxidase inhibitor, in patients with advanced myelofibrosis as an add-on to ruxolitinib treatment for up to 52 weeks

Category Primary study
Conference67th American Society of Hematology Annual Meeting, ASH 2025
Year 2025
This article has no abstract
Epistemonikos ID: 0b8b21cd06972bd564b748c62a59f2d7cf337fa5
First added on: Jun 15, 2026